全文获取类型
收费全文 | 15819篇 |
免费 | 1000篇 |
国内免费 | 89篇 |
专业分类
耳鼻咽喉 | 158篇 |
儿科学 | 295篇 |
妇产科学 | 263篇 |
基础医学 | 2148篇 |
口腔科学 | 156篇 |
临床医学 | 1447篇 |
内科学 | 3806篇 |
皮肤病学 | 280篇 |
神经病学 | 1669篇 |
特种医学 | 734篇 |
外科学 | 2729篇 |
综合类 | 36篇 |
一般理论 | 2篇 |
预防医学 | 710篇 |
眼科学 | 140篇 |
药学 | 1064篇 |
中国医学 | 20篇 |
肿瘤学 | 1251篇 |
出版年
2023年 | 108篇 |
2022年 | 176篇 |
2021年 | 477篇 |
2020年 | 224篇 |
2019年 | 463篇 |
2018年 | 549篇 |
2017年 | 363篇 |
2016年 | 366篇 |
2015年 | 451篇 |
2014年 | 704篇 |
2013年 | 818篇 |
2012年 | 1302篇 |
2011年 | 1339篇 |
2010年 | 750篇 |
2009年 | 727篇 |
2008年 | 1089篇 |
2007年 | 1034篇 |
2006年 | 1053篇 |
2005年 | 935篇 |
2004年 | 885篇 |
2003年 | 730篇 |
2002年 | 707篇 |
2001年 | 156篇 |
2000年 | 114篇 |
1999年 | 135篇 |
1998年 | 127篇 |
1997年 | 112篇 |
1996年 | 88篇 |
1995年 | 76篇 |
1994年 | 71篇 |
1993年 | 47篇 |
1992年 | 67篇 |
1991年 | 45篇 |
1990年 | 45篇 |
1989年 | 58篇 |
1988年 | 53篇 |
1987年 | 38篇 |
1986年 | 37篇 |
1985年 | 32篇 |
1984年 | 24篇 |
1983年 | 25篇 |
1982年 | 16篇 |
1978年 | 17篇 |
1976年 | 13篇 |
1975年 | 22篇 |
1974年 | 25篇 |
1972年 | 17篇 |
1971年 | 14篇 |
1970年 | 21篇 |
1969年 | 18篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
Four-Year Follow-up on Endovascular Radiofrequency Obliteration of Great Saphenous Reflux 总被引:4,自引:0,他引:4
Merchant Robert F. MD Pichot Olivier MD † Myers Kenneth A. MD ‡ 《Dermatologic surgery》2005,31(2):129-134
BACKGROUND: Endovascular radiofrequency obliteration has been used since 1998 as an alternative to conventional vein stripping surgery for elimination of saphenous vein insufficiency. OBJECTIVE: To demonstrate the long-term efficacy of this treatment modality. METHODS: Data were prospectively collected in a multicenter ongoing registry. Only great saphenous vein above-knee treatments were included in this study. Eight hundred ninety patients (1,078 limbs) were treated prior to November 2003 at 32 centers. Clinical and duplex ultrasound follow-up was performed at 1 week, 6 months, and 1, 2, 3, and 4 years. RESULTS: Among 1,078 limbs treated, 858 were available for follow-up within 1 week, 446 at 6 months, 384 at 1 year, 210 at 2 years, 114 at 3 years, and 98 at 4 years. The vein occlusion rates were 91.0%, 88.8%, 86.2%, 84.2%, and 88.8%, respectively; the reflux-free rates were 91.0%, 89.3%, 86.2%, 86.0%, and 85.7%, respectively; and the varicose vein recurrence rates were 7.2%, 13.5%, 17.1%, 14.0%, and 21.4%, respectively, at each follow-up time point at 6 months, and 1, 2, 3, and 4 years. Patient symptom improvement persisted over 4 years. CONCLUSIONS: Endovascular temperature-controlled radiofrequency obliteration of saphenous vein reflux exhibits an enduring treatment efficacy clinically, anatomically, and hemodynamically up to 4 years following treatment. 相似文献
12.
Ladenstein Ruth; Pearce Rachel; Hartmann Olivier; Patte Catherine; Goldstone Tony; Philip Thierry 《Blood》1997,90(8):2921-2930
13.
Somaini Bertino Billo Nils Dubois Jean-Alain Staub Roger 《International journal of public health》1988,33(7):340-344
International Journal of Public Health - Die Übertragungswege des HIV, welche in der Bevölkerung eine Rolle spielen, sind heute bekannt. Neben der sexuellen Übertragung, der... 相似文献
14.
Marc Ziegler Alexandre Castro-Caldas Susanna Del Signore Olivier Rascol 《Movement disorders》2003,18(4):418-425
Piribedil is a non-ergot D2/D3 agonist with a significant antagonist action on alpha2A and alpha2C adrenergic receptor subtypes. This double-blind placebo-controlled study was undertaken to confirm the efficacy of 150 mg/day piribedil po in improving motor symptoms of idiopathic Parkinson's disease (PD) in nonfluctuating patients insufficiently controlled by a stable daily dose of levodopa (L-dopa). Efficacy was assessed using the Unified Parkinson's Disease Rating Scale (UPDRS) III score as primary criterion over 4 months. A second comparison was planned at 6 months, after possible adjustment of L-dopa. At 4 months, the rate of response, defined as a 30% decrease from baseline on UPDRS III score, was significantly greater with piribedil compared with placebo (56.4% vs. 37.7%; P = 0.040). At 6 months, the better efficacy of piribedil was maintained (61.8% of responders vs. 39.6% on placebo; P = 0.020). The difference between groups on UPDRS III change from baseline reached statistical significance only at 6 months: -10.0 points in the piribedil group vs. -6.7 points in the placebo group (P = 0.037). Secondary end-points were not significantly different. The most frequently reported adverse events were gastrointestinal symptoms (27 of 61 patients in the piribedil group vs. 13 of 54 patients in the placebo group). In conclusion, a 6-month oral administration of 150 mg/day piribedil in combination with L-dopa is well tolerated, except for minor gastrointestinal symptoms at the beginning of the treatment and significantly improves motor symptoms compared with placebo in PD nonfluctuating patients. 相似文献
15.
16.
17.
Catherine Beckers Clio Ribbens Béatrice André Stefaan Marcelis Olivier Kaye Luc Mathy Marie-Jo?lle Kaiser Roland Hustinx Jacqueline Foidart Michel G Malaise 《Journal of nuclear medicine》2004,45(6):956-964
The aim of this study was to assess synovitis by (18)F-FDG PET in an individual joint analysis and in a global analysis of rheumatoid arthritis (RA) disease activity and to compare (18)F-FDG PET parameters with clinical, biologic, and sonographic (US) rheumatoid parameters. METHODS: Three hundred fifty-six joints were assessed in 21 patients with active RA: the knees in all subjects and either wrists as well as metacarpophalangeal and proximal interphalangeal joints in 13 patients, or ankles and the first metatarsophalangeal joints in the remaining 8 patients. PET analysis consisted of a visual identification of (18)F-FDG uptake in the synovium and measurements of standardized uptake values (SUVs). Independent assessors performed the clinical and US examinations. RESULTS: PET positivity was found in 63% of joints, whereas 75%, 79%, and 56% were positive for swelling, tenderness, and US analysis, respectively. Both the rate of PET-positive joints and the SUV increased with the number of positive parameters present (swelling, tenderness, US positivity) and with the synovial thickness. The mean SUV was significantly higher in joints where a power Doppler signal was found. In a global PET analysis, the number of PET-positive joints and the cumulative SUV were significantly correlated with the swollen and tender joint counts, the patient and physician global assessments, the erythrocyte sedimentation rate and C-reactive protein serum levels, the disease activity score and the simplified disease activity index, the number of US-positive joints, and the cumulative synovial thickness. CONCLUSION: (18)F-FDG PET is a unique imaging technique that can assess the metabolic activity of synovitis and measure the disease activity in RA. 相似文献
18.
Pericardial puncture is the percutaneous insertion of a needle into the pericardial space to drain a pathological pericardial effusion. The challenge for the operating surgeon is to reach percutaneously a target zone in the vicinity of the mobile heart, in a soft-tissue environment. The surgeon's ability to accomplish this depends on his own mental picture of the effusion. CASPER is a navigation software using an optical localizer which assists the surgeon by enhancing the representation of the effusion and guiding the needle's progress. Using a localized and calibrated echographic probe, the surgeon acquires a set of images in the region of interest. This zone is then manually segmented on each image, a common zone is computed, and the surgeon defines a trajectory for the needle. During the puncture procedure, the surgeon follows the position of the localized needle on a computer monitor. After initial validation on an experimental phantom, a feasibility study was performed using canine and porcine models. The optical localization device was changed from an Optotrak to a Polaris device for easier use in the clinical setting. Prior to clinical application, various tests were performed concerning the mobility of the thoracic cage, the reproducibility of the thoracic position over several apneas, and the stability of anatomic structures relative to the thoracic cage. Finally, a first clinical application was successfully performed using this system. The present paper reports on these last two stages. 相似文献
19.
20.